SCA
AZN icon

Snowden Capital Advisors’s AstraZeneca AZN Stock Holding History

Snowden Capital Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.64M Sell
18,787
-475
-2% -$91.6K 0.1% 213
2025
Q4 		$3.54M Buy
19,262
+975
+5% +$171K 0.09% 216
2025
Q3 		$2.81M Sell
18,287
-83
-0.5% -$12.6K 0.08% 254
2025
Q2 		$2.57M Sell
18,370
-2,973
-14% -$417K 0.08% 256
2025
Q1 		$3.14M Sell
21,343
-371
-2% -$53.7K 0.1% 217
2024
Q4 		$2.85M Sell
21,714
-689
-3% -$96.5K 0.09% 225
2024
Q3 		$3.49M Buy
22,403
+243
+1% +$39.2K 0.1% 220
2024
Q2 		$3.46M Buy
22,160
+4,102
+23% +$617K 0.1% 227
2024
Q1 		$2.45M Sell
18,058
-380
-2% -$50.3K 0.08% 287
2023
Q4 		$2.48M Buy
18,438
+1,367
+8% +$178K 0.09% 246
2023
Q3 		$2.31M Sell
17,071
-824
-5% -$113K 0.1% 252
2023
Q2 		$2.56M Sell
17,895
-1,105
-6% -$163K 0.09% 250
2023
Q1 		$2.64M Buy
19,000
+1,629
+9% +$219K 0.1% 243
2022
Q4 		$2.36M Buy
17,371
+988
+6% +$124K 0.1% 252
2022
Q3 		$1.8M Buy
16,383
+9,406
+135% +$1.19M 0.08% 283
2022
Q2 		$921K Buy
6,977
+310
+5% +$40.7K 0.04% 441
2022
Q1 		$884K Buy
6,667
+4,014
+151% +$481K 0.04% 474
2021
Q4 		$309K Sell
2,653
-2,444
-48% -$288K 0.02% 563
2021
Q3 		$612K Buy
5,097
+35
+0.7% +$4.07K 0.03% 479
2021
Q2 		$606K Buy
5,062
+968
+24% +$106K 0.03% 486
2021
Q1 		$407K Buy
4,094
+537
+15% +$54K 0.02% 541
2020
Q4 		$356K Buy
3,557
+453
+15% +$48K 0.02% 499
2020
Q3 		$340K Sell
3,104
-1,118
-26% -$124K 0.03% 444
2020
Q2 		$447K Buy
4,222
+64
+2% +$6.61K 0.04% 398
2020
Q1 		$371K Buy
4,158
+683
+20% +$64.3K 0.04% 397
2019
Q4 		$346K Sell
3,475
-188
-5% -$17.7K 0.03% 457
2019
Q3 		$327K Sell
3,663
-64
-2% -$5.55K 0.03% 411
2019
Q2 		$308K Buy
3,727
+46
+1% +$3.61K 0.03% 409
2019
Q1 		$298K Sell
3,681
-580
-14% -$45.7K 0.03% 405
2018
Q4 		$324K Buy
4,261
+44
+1% +$3.44K 0.04% 371
2018
Q3 		$334K Buy
4,217
+1,134
+37% +$85.8K 0.04% 378
2018
Q2 		$216K Sell
3,083
-118
-4% -$8.49K 0.03% 411
2018
Q1 		$224K Sell
3,201
-983
-23% -$68.1K 0.03% 353
2017
Q4 		$290K Sell
4,184
-3,841
-48% -$259K 0.04% 336
2017
Q3 		$544K Sell
8,025
-944
-11% -$59.6K 0.09% 253
2017
Q2 		$611K Sell
8,969
-99
-1% -$6.46K 0.11% 215
2017
Q1 		$565K Sell
9,068
-602
-6% -$35K 0.12% 211
2016
Q4 		$528K Sell
9,670
-466
-5% -$26.5K 0.13% 189
2016
Q3 		$666K Buy
10,136
+4,708
+87% +$308K 0.18% 164
2016
Q2 		$328K Buy
+5,428
New +$315K 0.1% 216

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Snowden Capital Advisors's AZN Position: Q1 2026 in Review

Snowden Capital Advisors reduced its AstraZeneca (AZN) stake by 2.5% in Q1 2026, selling an estimated $91.6K and leaving 18,787 shares worth $3.64M. The position accounts for 0.1% of the portfolio, ranked #213.

Snowden Capital Advisors first reported a position in AZN in Q2 2016 and has held it in 40 quarters since. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Snowden Capital Advisors held 18,787 shares of AstraZeneca worth $3.64M as of Q1 2026.
  • Snowden Capital Advisors sold 475 AstraZeneca shares in Q1 2026, an estimated $91.6K.
  • AstraZeneca made up 0.1% of Snowden Capital Advisors's portfolio in Q1 2026, its #213 holding.
  • Snowden Capital Advisors first reported a position in AstraZeneca in Q2 2016 and has held it in 40 quarters since.
  • 1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.